Back to List View Graph View

Receptor-binding domain

A receptor-binding domain (RBD) is a protein region that specifically recognizes and binds a host-cell receptor.

Where the papers sit

11 papers from the last 6 months study receptor-binding domain directly · updated from PubMed 11 Nov 2026

Study type 0 clinical trials · 1 observational · 4 human data · 6 preclinical

Themes one subject · 1 paradigm shift

Those 11 are all about one subject.

  • SARS-CoV-2 RBD Immunity

    SARS-CoV-2 RBD research centers on defining and improving antibody-mediated immunity through vaccination, boosting, and engineered binders. Studies repeatedly assess breadth, durability, immune imprinting, variant escape, and conformational epitopes while tracking antibody titers and mRNA integrity. Multivalent RBD displays, dimeric mRNA vaccines, intranasal adenovirus, and virus-like particles aim to broaden protection against divergent variants and SARS-CoV-1. The work remains exploratory, spanning human kinetics, animal protection, diagnostics, and binder design rather than establishing one dominant strategy.

    11 papers

PARADIGM SHIFT

Broad variant protection requires multivalent RBD presentation rather than reliance on a single RBD antigen

The heterodimeric KP.3/key-mutant RBD mRNA vaccine in mice 42687061Sep and the intranasal chimpanzee adenovirus vaccine expressing tandem RBDs from SARS-CoV-2, SARS-CoV, and MERS-CoV in mice and Syrian hamsters 42497177Jul each found that combining antigenically distinct RBDs produced broad protection across divergent SARS-CoV-2 variants, with the latter also extending protection to SARS-CoV and limiting transmission. This reverses the assumption that a single optimized RBD is an adequate basis for variant-resilient vaccination: vaccine design shifts toward deliberately multivalent RBD architectures to broaden and durablely sustain immunity.

Papers

The 11 papers from the last 6 months that study receptor-binding domain directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.

By theme

SARS-CoV-2 RBD Immunity (11)
  1. Design Trade-Offs between Target Binding and Self-Association Revealed by De Novo SARS-CoV-2 Binders. Journal of chemical information and modeling · 9 Nov 2026 PMID 43001931
  2. In Vivo Blood Kinetics and Transcript Integrity of Three mRNA-Lipid Nanoparticle Vaccines in Humans. ACS nano · 27 Oct 2026 PMID 42937588
  3. Twenty-year persistence of SARS-CoV-1 immune imprinting shapes antibody responses to SARS-CoV-2 infection. Immunity · 7 Sept 2026 PMID 42705227
  4. Virus-like particle display of the SARS-CoV-2 receptor-binding domain using a modular tag/catcher system enhances immunogenicity of a DNA vaccine in mice. Vaccine · 5 Sept 2026 PMID 42700748
  5. A dimeric mRNA vaccine based on key-mutant and KP.3 RBDs induces broad-spectrum immunity and protects mice against JN.1 and XDV challenges. Molecular biomedicine · 3 Sept 2026 PMID 42687061
  6. Functional neutralizing and bactericidal antibody responses induced by dual-target immunization with SARS-CoV-2 RBD and Neisseria meningitidis antigens in mice. Vaccine · 12 Aug 2026 PMID 42585813
  7. Anti-SARS-CoV-2 receptor-binding domain IgG titers and associated factors after heterologous mRNA booster vaccination in individuals primed with the inactivated vaccine. Acta tropica · 31 Jul 2026 PMID 42537920
  8. Anti-RBD Single-Chain Variable Fragments Library (scFv Library) Generation toward the Development of a Diagnostic Platform for SARS-CoV-2. ACS infectious diseases · 27 Jul 2026 PMID 42504989
  9. Broad and durable protection against SARS-CoV-2 and SARS-CoV by an intranasal chimpanzee adenovirus vaccine expressing tandem RBDs and nucleocapsid. PLoS pathogens · 24 Jul 2026 PMID 42497177
  10. Evaluating SARS-CoV-2 antibody resilience via prediction and design of escape viral variants. Cell systems · 17 Jul 2026 PMID 42468530
  11. Mass spectrometry-based mapping of conformational epitopes on SARS-CoV-2 antigens targeted by monoclonal antibodies. International journal of biological macromolecules · 21 Jun 2026 PMID 42324012

By study type

Observational studies and case reports (1)
  1. Anti-SARS-CoV-2 receptor-binding domain IgG titers and associated factors after heterologous mRNA booster vaccination in individuals primed with the inactivated vaccine. Acta tropica · 31 Jul 2026 PMID 42537920
Human data, design not indexed (4)
  1. Design Trade-Offs between Target Binding and Self-Association Revealed by De Novo SARS-CoV-2 Binders. Journal of chemical information and modeling · 9 Nov 2026 PMID 43001931
  2. In Vivo Blood Kinetics and Transcript Integrity of Three mRNA-Lipid Nanoparticle Vaccines in Humans. ACS nano · 27 Oct 2026 PMID 42937588
  3. Evaluating SARS-CoV-2 antibody resilience via prediction and design of escape viral variants. Cell systems · 17 Jul 2026 PMID 42468530
  4. Mass spectrometry-based mapping of conformational epitopes on SARS-CoV-2 antigens targeted by monoclonal antibodies. International journal of biological macromolecules · 21 Jun 2026 PMID 42324012
Preclinical: animal, cell and lab studies (6)
  1. Twenty-year persistence of SARS-CoV-1 immune imprinting shapes antibody responses to SARS-CoV-2 infection. Immunity · 7 Sept 2026 PMID 42705227
  2. Virus-like particle display of the SARS-CoV-2 receptor-binding domain using a modular tag/catcher system enhances immunogenicity of a DNA vaccine in mice. Vaccine · 5 Sept 2026 PMID 42700748
  3. A dimeric mRNA vaccine based on key-mutant and KP.3 RBDs induces broad-spectrum immunity and protects mice against JN.1 and XDV challenges. Molecular biomedicine · 3 Sept 2026 PMID 42687061
  4. Functional neutralizing and bactericidal antibody responses induced by dual-target immunization with SARS-CoV-2 RBD and Neisseria meningitidis antigens in mice. Vaccine · 12 Aug 2026 PMID 42585813
  5. Anti-RBD Single-Chain Variable Fragments Library (scFv Library) Generation toward the Development of a Diagnostic Platform for SARS-CoV-2. ACS infectious diseases · 27 Jul 2026 PMID 42504989
  6. Broad and durable protection against SARS-CoV-2 and SARS-CoV by an intranasal chimpanzee adenovirus vaccine expressing tandem RBDs and nucleocapsid. PLoS pathogens · 24 Jul 2026 PMID 42497177